{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["56(6)"],"submitter":["Lavu A"],"pubmed_abstract":["<b>Purpose:</b> A 28-year-old male reported to our hospital with Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) overlap syndrome that developed as an adverse drug reaction (ADR) to allopurinol. <i>HLA-B*58:01</i> allele is associated with an increased risk of developing allopurinol-induced SJS/TEN. <b>Methods:</b> Genomic DNA was extracted from peripheral blood leukocytes. DNA sequencing was done using SANGER sequencing method. <b>Results:</b> Pharmacogenetic testing results revealed positive for <i>HLA-B*58:01</i> allele. Symptoms of the patient receded after allopurinol withdrawal. <b>Conclusion:</b> The thrust of personalized therapy is from decoding the individual specific genetic variations astutely for better therapeutic outcomes such as reducing the ADRs. Pharmacogenetic testing is emerging as a safe, fast, and economic screening tool for personalized therapy by preventing ADRs. Pharmacogenetic <i>HLA-B*58:01</i> allele testing before allopurinol administration could significantly reduce the incidence of SJS/TEN and associated mortalities/morbidities and thereby represent a potential cost-effective intervention."],"journal":["Hospital pharmacy"],"pagination":["660-663"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8559029"],"repository":["biostudies-literature"],"pubmed_title":["Clinical Utility of <i>HLA-B*58:01</i> Genotyping to Prevent Allopurinol-Induced SJS/TEN."],"pmcid":["PMC8559029"],"pubmed_authors":["Thomas L","Saravu K","Lavu A","Thiriveedi S","Rao M","Khera K"],"additional_accession":[]},"is_claimable":false,"name":"Clinical Utility of <i>HLA-B*58:01</i> Genotyping to Prevent Allopurinol-Induced SJS/TEN.","description":"<b>Purpose:</b> A 28-year-old male reported to our hospital with Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) overlap syndrome that developed as an adverse drug reaction (ADR) to allopurinol. <i>HLA-B*58:01</i> allele is associated with an increased risk of developing allopurinol-induced SJS/TEN. <b>Methods:</b> Genomic DNA was extracted from peripheral blood leukocytes. DNA sequencing was done using SANGER sequencing method. <b>Results:</b> Pharmacogenetic testing results revealed positive for <i>HLA-B*58:01</i> allele. Symptoms of the patient receded after allopurinol withdrawal. <b>Conclusion:</b> The thrust of personalized therapy is from decoding the individual specific genetic variations astutely for better therapeutic outcomes such as reducing the ADRs. Pharmacogenetic testing is emerging as a safe, fast, and economic screening tool for personalized therapy by preventing ADRs. Pharmacogenetic <i>HLA-B*58:01</i> allele testing before allopurinol administration could significantly reduce the incidence of SJS/TEN and associated mortalities/morbidities and thereby represent a potential cost-effective intervention.","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Dec","modification":"2025-04-26T09:45:26.921Z","creation":"2025-04-06T13:07:42.011Z"},"accession":"S-EPMC8559029","cross_references":{"pubmed":["34732918"],"doi":["10.1177/0018578720934972"]}}